search
Back to results

Methorexate and Knee Osteoarthritis

Primary Purpose

Pain Reduction, Physical Function Improvement

Status
Completed
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
25 mg/week oral methotrexate tablets
25mg/week oral placebo tablets
Sponsored by
University of Alexandria
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain Reduction focused on measuring methotrxate, knee osteoarthritis, inflammation, pain, function

Eligibility Criteria

60 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • primary knee osteoarthritis
  • synovitis
  • pain

Exclusion Criteria:

  • other inflammatory conditions
  • hepatic insufficiency
  • renal insufficiency

Sites / Locations

  • Faculty of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Methotrexate

Placebo

Arm Description

25mg oral MTX tablets

25 mg/week placebo tablets

Outcomes

Primary Outcome Measures

Pain reduction
The primary outcome measure was pain reduction.Pain was assessed using the Visual Analogue pain Scale, (VAS, 0-100 mm).

Secondary Outcome Measures

Physical function improvement
Functional assessment was performed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Activities of daily living (ADL) scores.

Full Information

First Posted
August 8, 2013
Last Updated
March 27, 2020
Sponsor
University of Alexandria
search

1. Study Identification

Unique Protocol Identification Number
NCT04326894
Brief Title
Methorexate and Knee Osteoarthritis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
December 2011 (Actual)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
December 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alexandria

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Osteoarthritis (OA) is considered a complex, multifactorial disease leading to considerable pain and functional disability amongst older adults in particular.Synovial inflammation and proliferation has emerged as a key component of OA and as a potential predictor of worsening disease. Methotrexate (MTX) is widely used in the treatment of all inflammatory rheumatic diseases. Accordingly, the aim of the present study is to assess the efficacy of methotrexate (MTX) in decreasing pain and inflammation in symptomatic knee OA. 128 patients with clinical and radiographic criteria of primary knee OA pain,were recruited. Patients meeting the eligibility criteria are randomized in a 1:1 ratio to receive either 25mg/week oral MTX (n=64) or placebo (n=64) together with their usual therapy provided the dosages are kept constant for 32 weeks. The primary outcome measure is pain reduction and secondary outcome measures is improvement in physical function scores. Keywords: methotrexate knee osteoarthritis inflammation pain reduction physical funtion

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain Reduction, Physical Function Improvement
Keywords
methotrxate, knee osteoarthritis, inflammation, pain, function

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
128 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Methotrexate
Arm Type
Experimental
Arm Description
25mg oral MTX tablets
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
25 mg/week placebo tablets
Intervention Type
Drug
Intervention Name(s)
25 mg/week oral methotrexate tablets
Other Intervention Name(s)
interventional drug
Intervention Type
Drug
Intervention Name(s)
25mg/week oral placebo tablets
Primary Outcome Measure Information:
Title
Pain reduction
Description
The primary outcome measure was pain reduction.Pain was assessed using the Visual Analogue pain Scale, (VAS, 0-100 mm).
Time Frame
8 months
Secondary Outcome Measure Information:
Title
Physical function improvement
Description
Functional assessment was performed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Activities of daily living (ADL) scores.
Time Frame
8 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: primary knee osteoarthritis synovitis pain Exclusion Criteria: other inflammatory conditions hepatic insufficiency renal insufficiency
Facility Information:
Facility Name
Faculty of Medicine
City
Alexandria
ZIP/Postal Code
00203
Country
Egypt

12. IPD Sharing Statement

Learn more about this trial

Methorexate and Knee Osteoarthritis

We'll reach out to this number within 24 hrs